Cell membrane blebbing, chromatin condensation, genomic DNA fragmentation, and the exposure of particular phagocytosis signaling molecules on the cell surface are just a few of the distinctive morphological and biochemical features of the cell death process known as apoptosis. Apoptosis-initiated cell death is distinct from necrosis-induced cell death. Apoptotic death, in contrast, is silent and orderly. Necrotic cells are typically recognized as a danger signal by the immune system, which causes inflammation.
There are two main methods for inducing apoptotic cell death: The intrinsic pathway, also known as the Bcl-2-regulated or mitochondrial pathway, is strictly regulated by the BCL-2 family of proteins and is activated by a variety of developmental cues or cytotoxic insults, such as viral infection, DNA damage, and growth-factor deprivation.The tumor necrosis factor (TNF) receptor family members, such as Fas or TNF receptor-1 (TNFR1), which contain an intracellular death domain and can recruit and activate caspase-8 through the adaptor protein Fas-associated death domain (FADD; also known as MORT1) at the cell surface, are what initiate the extrinsic or death-receptor pathway. Without the involvement of the BCL-2 family, this recruitment results in the subsequent activation of downstream (effector) caspases like caspase-3, -6, or -7.
Numerous human diseases, including cancer, viral infections, autoimmune diseases, neurodegenerative disorders, and AIDS (acquired immunodeficiency syndrome), may be influenced by changes in cell survival, according to studies. Some of these diseases may not progress naturally unless specific therapies that change the apoptotic threshold are used.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V52368 | Azaphilone-9 (AZA-9) | 1448460-87-4 | Azaphilone-9 (AZA-9) is an inhibitor that can suppress the HuR-ARE RNA interaction via binding to the RNA-binding protein Hu antigen R (HuR) (IC50=1.2 μM). |
|
V52659 | Azilsartan-d4 (TAK-536-d4) | 1794817-45-0 | Azilsartan-d4 is the deuterated form of Azilsartan. |
|
V3175 | Azoramide | 932986-18-0 | Azoramide is a small-molecule modulator ofthe unfolded protein response (UPR) and an ER stress alleviator that is reported to haveantidiabetic activity. |
|
V34726 | AZT triphosphate tetraammonium (3'-Azido-3'-deoxythymidine-5'-triphosphate tetraammonium) | 106060-92-8 | AZT triphosphate (3'-Azido-3'-deoxythymidine-5'-triphosphate) tetraammonium is an active triphosphate metabolite of Zidovudine (AZT). |
|
V56436 | Azurin p28 peptide | 897026-25-4 | Azurin p28 peptide is a tumor-penetrating anti-tumor peptide. |
|
V54865 | Baceridin | 1622872-91-6 | Baceridin is a proteasome inhibitor and a cyclic hexapeptide. |
|
V54925 | BAD (103-127) (human) (BADBH3 103-127 (human); BADBH3 (human)) | 331762-68-6 | BAD (103-127) (human) is a 25-mer Bad polypeptide extracted from the BH3 domain of BAD, which can antagonize the effects of Bcl-xL. |
|
V54938 | Bad BH3 (mouse) | 505070-07-5 | Bad BH3 (mouse) is a biologically active peptide. |
|
V52367 | Bafilomycin C1 (Bafilomycin C1) | 88979-61-7 | Bafilomycin C1 is a macrolide antibiotic (antibiotic) extracted from Streptomyces sp. |
|
V84697 | BAI1 hydrochloride | 329349-20-4 | |
|
V52366 | Bak BH3 | 300349-67-1 | Bak BH3 is a polypeptide extracted from the BH3 domain of Bak protein, which can inhibit the activity of Bcl-xL in cells. |
|
V52365 | Balanophonin | 80286-36-8 | Balanophonin is an anti~inflammatory and anti-cancer agent. |
|
V35065 | Bax BH3 peptide (55-74), wild type | 299946-20-6 | Bax BH3 peptide (55-74), wild type is a 20-amino acid (AA) Bax BH3 peptide (Bax 1) that can cause apoptosis in a variety of cell line models. |
|
V54935 | Bax inhibitor peptide, negative control | 1315378-74-5 | Bax inhibitor peptide, negative control (NC) is an inhibitor (blocker/antagonist) of Bax. |
|
V52359 | BC-1258 | 1507370-40-2 | BC-1258 is an F-box/LRR-repeat protein 2 (FBXL2) activator that stabilizes and upregulates FBXL2 levels. |
|
V52357 | Bcl-2-IN-11 | 2760536-88-5 | Bcl-2-IN-11 (compound 6) is a potent and specific inhibitor of Bcl-2 activity with IC50 of 0.9 nM. |
|
V52356 | Bcl-2-IN-2 | 2383085-86-5 | Bcl-2-IN-2 is a potent and specific Bcl-2 inhibitor (antagonist) with IC50 of 0.034 nM. |
|
V54928 | Bcl-B inhibitor 1 | 79220-88-5 | Bcl-B inhibitor 1 is an inhibitor (blocker/antagonist) of Bcl-B. |
|
V53148 | Bcl-xL antagonist 2 | 1235032-75-3 | Bcl-xL antagonist 2 is a specific, orally bioactive BCL-XL antagonist. |
|
V52355 | BCL6 PROTAC 1 | 2257479-54-0 | BCL6 PROTAC 1 is a selective B-cell lymphoma 6 (BCL6) PROTAC. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
